You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 歌禮制藥-B(1672.HK)一度漲近7% 利托那韋片完成浙江省首單銷售
格隆匯 04-06 10:16
格隆匯4月6日丨歌禮制藥-B(1672.HK)盤初一度拉昇漲近7%,現報5.89港元,總市值64億港元。於4月3日利托那韋片完成浙江省首單銷售。歌禮表示,利托那韋片年產能已擴大至約5.3億片,以保障供應,並已向德國、法國、愛爾蘭、英國等共12個歐洲國家及香港地區遞交利托那韋(100毫克薄膜衣片)上市許可申請,產品已於2021年9月獲中國國家藥品監督管理局批准上市。據悉,歌禮擁有目前中國唯一通過生物等效性研究獲批上市的利托那韋片。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account